Skip to content

Safety and Efficacy of Low-dose Heparin during Intracranial Angioplasty and Stent placement: a randomized, double-blind, controlled study of 2000 IU versus 3000 IU bolus heparin

Safety and Efficacy of Low-dose Heparin during Intracranial Angioplasty and Stent placement: a randomized, double-blind, controlled study of 2000 IU versus 3000 IU bolus heparin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN48605341
Enrollment
60
Registered
2005-09-14
Start date
2005-02-01
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial angioplasty Surgery Ischemic stroke attributed to an intracranial stenosis

Interventions

Stent-assisted angioplasty of the offending intracranial stenosis

Sponsors

The Ministry of Health of the People's Republic of China
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. 18-75 years of age 2. Recurrent ischemic events (transient ischemic attack and/or stroke) attributed to an intracranial stenosis = 50% at digital subtraction angiography (DSA) 3. Performed intracranial angioplasty and stent placement

Exclusion criteria

Exclusion criteria: 1. Intracranial hemorrhage and major ischemic stroke (NIHSS =8) in the same hemisphere as the target lesion within 6 weeks 2. Concurrent severe extracranial artery stenosis and angioplasty and stent placement needed to be performed 3. Concurrent intracranial tumors, cerebral AVM and aneurysms 4. History of heparin allergy 5. Received perioperative heparin or surgical procedures requiring systemic heparinization 6. Preoperative platelet or coagulation abnormalities 7. Patients were not eligible if they could not cooperate with the study procedures or provide informed consent

Design outcomes

Primary

MeasureTime frame
1. Efficacy end point was thromboembolus complications within 24h. 2. Safety end point was intracranial bleeding complications within 24h.

Secondary

MeasureTime frame
1. Intraoperative activated clotting time monitoring 2. Puncture site complications

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026